These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26627251)

  • 41. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
    Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
    PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experimental study of K562 cell apoptosis induced by siRNA].
    Chen BB; Fan HH; Lin GW; Yuan ZH; Lu HZ; Gao L; Liu Y
    Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):717-9. PubMed ID: 15730712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
    Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
    Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
    Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
    Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
    Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
    Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective leukemia cell death by activation of the double-stranded RNA-dependent protein kinase PKR.
    Li YJ; Zeng JM; Huang SF; Wang XZ; Zhao SQ; Bai WJ; Cao WX; Huang ZG; Feng WL
    Int J Mol Med; 2011 Aug; 28(2):215-22. PubMed ID: 21468538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
    Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
    Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy.
    Acharya S; Sahoo SK
    Biomaterials; 2011 Aug; 32(24):5643-62. PubMed ID: 21600647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
    Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
    Clin Exp Med; 2007 Jun; 7(2):47-55. PubMed ID: 17609876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
    Zhu X; Li Y; Luo X; Fei J
    Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
    Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
    Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
    Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Stable interference on P210(bcr/abl) gene expression by lentiviral vector-delivered shRNA in vitro and in vivo].
    Zhu YF; Wang YZ; Meng FY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1090-4. PubMed ID: 23114125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.